%0 Journal Article %T Monoclonal Antibodies as Potential Treatment Drugs for Nsp15 and 3CLpro Proteins %J Physical Chemistry Research %I Iranian Chemical Society %Z 2322-5521 %A Alshammari, Shifaa O. %A Al-Mazaideh, Ghassab M. %A Alakhras, Fadi %A Huneif, Mohammed Ayed %A Ali Shah, Syed Imran %A Ahmad, Ashfaq %A Ayyal Salman, Haya %A Helmy Faris Shalayel, Mohammed %D 2023 %\ 09/01/2023 %V 11 %N 3 %P 623-629 %! Monoclonal Antibodies as Potential Treatment Drugs for Nsp15 and 3CLpro Proteins %K COVID-19 %K Antibody-Antigen docking %K cetuximab %R 10.22036/pcr.2022.351595.2147 %X Selected monoclonal antibody molecules were conducted using the antibody–antigen docking mode, as well as the antibody-antigen docking approach.Objective of the study was to check effects of CetuximabCOVID-19 proteins (Nsp15 and 3CLpro) by using antibody–antigen docking mode, as well as the antibody-antigen docking approach.The results of molecular docking revealed that Cetuximab, a cancer-fighting antibody, ranks first among antibodies to both COVID-19 proteins (Nsp15 and 3CLpro).In cetuximab–3CLpro and cetuximab–Nsp15 complexes, the antigen interacts with both antibody chains, H and L.According to the findings, Cetuximab can be added to the COVID-19 treatment protocol, which may have the desired effect of inhibiting viral replication and decreasing mortality by targetingCOVID-19 proteins (Nsp15 and 3CLpro).Validation of these computational findings will require additional in vitro and in vivo research, which can be considered as a contribution in the field of biotechnology %U https://www.physchemres.org/article_158452_15f5ecbb5334c4f00a71cb5755230765.pdf